SLPI Rabbit Polyclonal Antibody

CAT#: AP26394PU-N

SLPI rabbit polyclonal antibody, Purified



Need it in bulk or conjugated?
Get a free quote

CNY 7,031.00


货期*
5周

规格
    • 100 ug

Product images

Specifications

Product Data
Applications ELISA, IP, WB
Recommend Dilution Immunoassays.
Immunoprecipitation.
Western blot: The typical starting working dilution is 1:10.
Reactivity Human
Host Rabbit
Clonality Polyclonal
Specificity

The antibody reacts with secretory leukocyte proteinase inhibitor (SLPI; also known as antileukoprotease (ALP)).

Formulation PBS
State: Purified
State: Luiquid 0.2 µm filtered Ig fraction
Stabilizer: 0.1% bovine serum albumin
Preservative: 0.02% sodium azide
Concentration lot specific
Purification Protein A
Conjugation Unconjugated
Storage Condition

Store at 2 - 8 °C.

Gene Name secretory leukocyte peptidase inhibitor
Background SLPI is a 11.7 kDa cationic inhibitor of neutrophil elastase and to a lesser extent of cathepsin G. It is locally produced by epithelial cells in the lung, skin and other organs, by Polymorphonuclear leukocytes (PMN) and (in mice) by macrophages. In addition to its proteinase inhibitory properties that may serve to protect against proteolytic injury, it was recently shown that SLPI also displays several other functions such as antimicrobial and anti-inflammatory activities. These appear to be independent of its ability to inhibit PMN serine proteinases. SLPI has also been demonstrated to display antibacterial and antifungal activity at concentrations in which SLPI is present in mucosal secretions including those of the lung. Another possible role for SLPI is inhibition of protein-disulphide isomerase that is considered essential for invasion of a cell by the Human Immunodeficiency Virus (HIV).
Synonyms SLPI, WAP4, WFDC4
Reference Data
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.
Customer Reviews 
Loading...